propranolol has been researched along with osteoprotegerin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baroukh, B; Bataille, C; Brun, A; Chaussain, C; Cherruau, M; Haÿ, E; Marie, PJ; Mauprivez, C; Saffar, JL | 1 |
| Day, D; Steel, R | 1 |
2 other study(ies) available for propranolol and osteoprotegerin
| Article | Year |
|---|---|
Different sympathetic pathways control the metabolism of distinct bone envelopes.
Topics: Animals; Cholinergic Fibers; Femur; Gene Expression Regulation; Guanethidine; Isoproterenol; Macrophage Colony-Stimulating Factor; Male; Mandible; Osteogenesis; Osteoprotegerin; Periosteum; Propranolol; RANK Ligand; Rats; Rats, Wistar; Receptors, Adrenergic, beta-2; Receptors, Vasoactive Intestinal Peptide; RNA, Messenger; Sympathectomy; Sympathetic Nervous System; Time Factors; Tyrosine 3-Monooxygenase; Vasoactive Intestinal Peptide | 2012 |
Increased apoptosis and secretion of tryptase by mast cells in infantile haemangioma treated with propranolol.
Topics: Apoptosis; Biopsy; Case-Control Studies; Cell Degranulation; Endothelial Cells; Extracellular Matrix; Female; Hemangioma; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Infant; Mast Cells; Mesenchymal Stem Cells; Microvessels; Osteoprotegerin; Propranolol; Subcutaneous Tissue; Tryptases; Vasodilator Agents | 2014 |